Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Unichem Lab shares jump over 7 pc after USFDA nod for Atenolol tablets

      Unichem Lab shares jump over 7 pc after USFDA nod for Atenolol tablets

      Medical Dialogues Bureau27 Nov 2019 3:45 AM
      New Delhi: Unichem Laboratories shares on Monday surged over 7 per cent after the company got approval from the US health regulator for Atenolol...
      Teva Pharma, Israeli institutes sign agreement to boost drug research on cancer treatments

      Teva Pharma, Israeli institutes sign agreement to boost drug research on cancer treatments

      Medical Dialogues Bureau27 Nov 2019 3:30 AM
      A partnership with Tel Aviv University will focus on research and development in cancer and brain studies, while a collaboration with the Weizmann...
      Minister informs Parliament about steps taken to promote affordable generic drugs

      Minister informs Parliament about steps taken to promote affordable generic drugs

      Medical Dialogues Bureau26 Nov 2019 11:00 AM
      New Delhi: The Minister in the Ministry of Chemicals and Fertilizers D V Sadananda Gowda recently informed the Parliament about the steps taken by the...
      Novartis strikes USD 9.7 billion deal to acquire cholesterol drugmaker The Medicines Co

      Novartis strikes USD 9.7 billion deal to acquire cholesterol drugmaker The Medicines Co

      Medical Dialogues Bureau26 Nov 2019 9:30 AM
      Novartis is paying $85 per share in cash, a 24% premium over The Medicines Co's closing price of $68.55 on Friday, to acquire the U.S. biotechnology...
      Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal

      Aurobindo Pharma targets to achieve zero debt in three years sans Novartis deal

      Medical Dialogues Bureau26 Nov 2019 4:00 AM
      In September 2018, the USD three billion drug-maker, Aurobindo Pharma said its US subsidiary entered into an agreement to acquire commercial...
      Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020

      Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020

      Medical Dialogues Bureau26 Nov 2019 3:58 AM
      Roche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
      Novartis to buy biotech firm Medicines Co for about USD 7 billion: Report

      Novartis to buy biotech firm Medicines Co for about USD 7 billion: Report

      Medical Dialogues Bureau26 Nov 2019 3:45 AM
      The deal, in which Novartis has agreed to pay $85 a share, could be announced this weekend, the Journal reported, citing people familiar with the...
      Cancer drug Alunbrig compared to Xalkori shows longer benefit, says Takeda Pharma

      Cancer drug Alunbrig compared to Xalkori shows longer benefit, says Takeda Pharma

      Medical Dialogues Bureau26 Nov 2019 3:30 AM
      Alunbrig, Takeda Pharma's trade name of Brigatinib, reduced the risk of disease progression by 76% in patients whose cancer had spread to the brain...
      Torrent Pharma pulled up by USFDA for significant violations at US plant

      Torrent Pharma pulled up by USFDA for significant violations at US plant

      Medical Dialogues Bureau25 Nov 2019 6:45 AM
      In a warning letter issued to Torrent Pharma Inc's CEO Sanjay Gupta, the US Food and Drug Administration (USFDA) said its inspectors found significant...
      India, China spar over legacy of Sowa-Rigpa, medicinal system similar to Ayurveda

      India, China spar over legacy of Sowa-Rigpa, medicinal system similar to Ayurveda

      Medical Dialogues Bureau25 Nov 2019 4:03 AM
      “India has approached Unesco seeking the enlisting of the Sowa Rigpa as its ‘intangible cultural heritage’. China has raised an objection to it,” an...
      Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

      Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche

      Medical Dialogues Bureau25 Nov 2019 3:30 AM
      Median overall survival for patients with unresectable hepatocellular carcinoma (HCC), or that which cannot be surgically removed, getting Tecentriq...
      Producers of anti-venom, anti-toxin drugs respond to PETA PIL in Delhi High Court

      Producers of anti-venom, anti-toxin drugs respond to PETA PIL in Delhi High Court

      Medical Dialogues Bureau24 Nov 2019 6:00 AM
      New Delhi: Companies manufacturing anti-venom and anti-toxins by using horses and mules have told the Delhi High Court that exploring alternatives to...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok